Idrabiotaparinux sodium
Alternative Names: Biotinylated idraparinux; SSR 126517; SSR126517ELatest Information Update: 05 Nov 2023
At a glance
- Originator sanofi-aventis
- Developer Sanofi; sanofi-aventis
- Class Anticoagulants; Antithrombotics; Oligosaccharides
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Thrombosis
Highest Development Phases
- Discontinued Deep vein thrombosis; Embolism
Most Recent Events
- 11 Dec 2008 Efficacy data from the phase III EQUINOX trial in Deep vein thrombosis presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008) (ADNM)
- 03 Sep 2008 Pharmacodynamics data from a clinical trial in Thrombosis presented at the Congress of the European Society of Cardiology (ESC-2008)
- 30 Jul 2007 Data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH-2007) added to the Thromboses pharmacodynamics section